By: Luther T. Clark, MD Deputy Chief Patient Officer, Merck The COVID-19 pandemic has shone a light on longstanding health care disparities and amplified the importance of clinical trial diversity, especially participation of those patients and communities disproportionately impacted by the disease being studied. Since clinical trials function as the gatekeeper to bringing new medicines … Continued
The post Why clinical trial diversity is key to increasing access to routine care and innovative treatment options appeared first on The Michigan Chronicle.
